Lord, Abbett & Co’s Abivax ABVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.14M Buy
11,500
+2,000
+21% +$241K ﹤0.01% 543
2026
Q2
$1.27M Sell
9,500
-845,420
-99% -$95.7M ﹤0.01% 538
2026
Q1
$95.2M Buy
854,920
+5,188
+0.6% +$614K 0.31% 85
2025
Q4
$115M Buy
849,732
+513,026
+152% +$56M 0.35% 77
2025
Q3
$28.6M Buy
+336,706
New +$20.6M 0.09% 239

Other funds holding ABVX

Lord, Abbett & Co's ABVX Position: Q3 2026 in Review

Lord, Abbett & Co increased its Abivax (ABVX) stake by 21% in Q3 2026, buying an estimated $241K and bringing the position to 11,500 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Lord, Abbett & Co first reported a position in ABVX in Q3 2025 and has held it in 5 quarters since. The position peaked at $115M in Q4 2025. 319 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Lord, Abbett & Co held 11,500 shares of Abivax worth $1.14M as of Q3 2026.
  • Lord, Abbett & Co bought 2,000 Abivax shares in Q3 2026, an estimated $241K.
  • Abivax made up ﹤0.01% of Lord, Abbett & Co's portfolio in Q3 2026, its #543 holding.
  • Lord, Abbett & Co first reported a position in Abivax in Q3 2025 and has held it in 5 quarters since.
  • Lord, Abbett & Co's Abivax position peaked at $115M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.